SCHEMBL24897136

SCHEMBL24897136

CC(C)(C)OC(=O)NCCN1CCC(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.53
SIGMAR1 Q99720 3/20 0.52
CTSL P07711 1/20 0.48
EGFR P00533 2/20 0.48
SYK P43405 1/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
LTA4H P09960 1/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
IDO1 P14902 1/20 0.46
FKBP1A P62942 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25431020 0.94 SIGMAR1 (0.56) DRD2SIGMAR1CTSLEGFRKEAP1
SCHEMBL20191140 0.86 KCNA3 (0.56) DRD2SIGMAR1CTSLSYKKEAP1
SCHEMBL30803531 0.85 DRD2 (0.51) DRD2SIGMAR1SYKKEAP1NFE2L2
SCHEMBL3841942 0.84 KCNA3 (0.58) DRD2SIGMAR1CTSLSYKKEAP1
SCHEMBL31122439 0.84 ACHE (0.51) DRD2SIGMAR1SYKKEAP1NFE2L2
SCHEMBL514343 0.83 SIGMAR1 (0.61) DRD2SIGMAR1SYKMEN1ALDH1A1
SCHEMBL20479776 0.82 CTSL (0.54) DRD2SIGMAR1CTSLSYKKEAP1
SCHEMBL20974399 0.82 CTSL (0.54) DRD2SIGMAR1CTSLSYKKEAP1
SCHEMBL28688163 0.82 CTSL (0.54) DRD2SIGMAR1CTSLSYKKEAP1
SCHEMBL606732 0.82 CTSL (0.52) CTSLSYKMEN1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482583-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2025-01-01 EP disclosed
CN-118119609-A Imidazole derivatives and their use as antibiotics 豪夫迈·罗氏有限公司 2024-05-31 CN disclosed
US-11858912-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-01-02 US disclosed
WO-2023161316-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-31 WO disclosed
US-20230133845-A1 NOVEL HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed
WO-2023285497-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS F. HOFFMANN-LA ROCHE AG (CH) 2023-01-19 WO disclosed
WO-2023285497-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS F. HOFFMANN-LA ROCHE AG (CH) 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858912-B2 Heterocyclic compounds F12, C1R, MRPL21 DRD2 161/4885SIGMAR1 429/4885CTSL 2118/4885
US-20230133845-A1 NOVEL HETEROCYCLIC COMPOUNDS F12, PM20D2, XDH DRD2 254/4885SIGMAR1 195/4885CTSL 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.